FrontPoint's Skowron Charged In Insider-Trading Case

Apr 13 2011 | 11:18am ET

FrontPoint Partners healthcare chief Joseph Skowron was arrested today and charged with insider-trading.

Skowron surrendered to the Federal Bureau of Investigation this morning. According to prosecutors, he used confidential information about Human Genome Sciences supplied by a French doctor, who advised the pharmaceutical, to help his hedge funds at FrontPoint avoid $30 million in losses.

Skowron's alleged tipster, Yves Benhamou, a prominent nephrologist, pleaded guilty on Monday as part of a deal with prosecutors, the U.S. Attorney's office in New York said today. Benhamou, who consulted with at least six hedge funds, was arrested in November.

While authorities only publicly named FrontPoint and Skowron as the hedge fund and hedge fund manager referred to in their complaint against Benhamou, the two were quickly identified in the press, and FrontPoint acknowledged that it was the hedge fund in the case. Investors quickly ran for the door, leading FrontPoint to liquidate its healthcare hedge funds and shutter its healthcare unit, laying off its healthcare team. Skowron himself has been on leave since Benhamou's arrest.

"Dr. Benhamou has acknowledged his serious mistakes in judgment and intends to live up to his obligations under his cooperation agreement," Benhamou's lawyer, David Zornow of Skadden, said. "Dr. Benhamou's conduct in this instance must fairly be considered in the overall context of his extraordinary contributions to his patients and to medical science."

According to prosecutors, Benhamou warned Skowron that a Human Genome hepatitis-C drug trial had produced disappointing results. FrontPoint sold 3.3 million shares of Human Genome in January 2008, before the company announced the results of the drug trial. The move saved the hedge fund some $30 million.

For its part, FrontPoint has continuously said it is "cooperating fully" with the investigation.

Skowron, who holds a Ph.D. in cellular and molecular biology from Yale University, is expected to appear in court later today. He formerly worked at Millennium Partners and SAC Capital Advisors.


In Depth

Will Liquid Alts’ Performance Sustain Future Asset Flows?

Aug 25 2014 | 10:34am ET

Liquid alternative investment funds saw the highest percentage of capital inflows...

Lifestyle

Hedgies, Economists and Musicians Mingle At Milkin Mixers In Hamptons

Aug 25 2014 | 6:00am ET

Leave it to Michael Milken to bring some gravitas and sweat to the Hamptons -- along...

Guest Contributor

Looking Ahead: What’s In Store For Managed Futures?

Aug 22 2014 | 12:52pm ET

The last five years were phenomenal for investors in equity indices. Will the next...

 

Editor's Note

    Get A Sneak Peak Of The Alpha Pages

    Aug 25 2014 | 11:21am ET

    As many of you know, FINalternatives was recently acquired by the owners of Futures magazine, a firm called The Alpha Pages LLC. Today marks the soft-launch of a new sister site for both publications. As its name suggests, The Alpha Pages will cover all types of alternative investments, going far beyond the more well-known ones such as hedge funds and private equity. Read more…

 

Futures Magazine

July/August 2014 Cover

The time was right

Commodities/Futures magazine launched at the precipice of a revolution in the futures industry—really a revolution in the idea of risk management—that would move it from a small niche industry to ...

The Alpha Pages

TAP July/August 2014 Cover

The Alpha Pages Interview: Senator Rand Paul

Senator Paul sat down in the debut series of the Alpha Pages Interview to discuss the broken tax code, regulation surrounding Bitcoin, and his plans for the 2016 Presidential election.